Company intelligence / Profile preview
Kapoose Creek Bio
- Ownership
- Private
- Development stage
- Preclinical
Overview
Kapoose Creek Bio has rapidly advanced two potent natural product-derived compounds targeting neurological indications. Both are in late-stage optimization prior to preclinical candidate nomination. The company leverages its proprietary AI-driven unEarth Rx™ platform—now enhanced by Adapsyn’s technology—to accelerate the discovery and development of novel small molecule therapeutics from nature.
- Therapeutic areas
- OncologyPsychiatryNeurologyInfectious Diseases
- Modalities
- small molecules (natural products, fungal-derived compounds)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Kapoose Creek Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kapoose Creek Bio.